89bio — Investor Presentation (February 2023)
47 slides from 89bio's investor presentation, Feb 15, 2023
Slide 1: Powerful Science Meaningful Medicines Changing Lives
Nasdaq: ETNB Powerful Science Meaningful Medicines Changing Lives February 2023 Exhibit 99.1
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. Other than statements of his
Slide 3: Corporate Highlights
Highly competitive profile with Phase 2 results demonstrating robust efficacy across multiple histological and metabolic endpoints with favorable tolerability profile Well-powered study with three-panel consensus biopsy reading method to minimize variability Nonalcoholic Steatohepatitis (NASH) – Pha
Slide 4: Pegozafermin is an FGF21 Analog Optimally Engineered
Pegozafermin is an FGF21 Analog Optimally Engineered to Balance Efficacy and Long Dosing Interval glycoPEG(20kD) C-terminus X Strong and flexible linker (glycoPEGylation technology) Mutations in positions 173 and 176 (glycoPEG attached at position 173) X N-terminus Position 182 FGF21 Proprietary gly
Slide 5: Proposed Mechanisms of Action of Pegozafermin
Stojsavljevic-Shapeski S et al J Clin Transl Hepatol 2021;9(1):51-59 Proposed Mechanisms of Action of Pegozafermin Adipose tissue Decrease lipogenesis and release of FFA Improve insulin resistance Increase TG uptake Increase adiponectin Liver Increase β-oxidation Decrease de novo lipogenesis Decreas
Slide 6: Opportunity in NASH
Opportunity in NASH
Slide 7: NASH is a Serious Liver Condition With Significant Co-Morbidities
NASH is a Serious Liver Condition With Significant Co-Morbidities No treatments currently available U.S. Prevalence of ~17.5 million patients in 2022 Fastest growing reason for a liver transplant in the United States Co-morbidity Prevalence in NASH population Hypertriglyceridemia 83% Obesity 82% Hyp
Slide 8: Phase 1b/2a NASH Trial Design
Phase 1b/2a NASH Trial Design 7 weeks SCREENING COHORT 1 COHORT 2 COHORT 3 COHORT 4 COHORT 5 COHORT 6 COHORT 7 SAFETY FOLLOW-UP Placebo (n=2) Placebo (n=3) Placebo (n=4) Placebo (n=3) Placebo (n=4) Placebo (n=3) 27mg QW (n=20) 3mg QW (n=6) 9mg QW (n=12) 18mg QW (n=11) 27mg QW (n10) 18mg Q2W (n=14) 3
Slide 9: Pegozafermin Demonstrated Robust Liver Fat Reduction
Mean Relative Reduction in Liver Fat vs Baseline Cohort 7 27mg QW Cohort 4 27mg QW Cohort 6 36mg Q2W Pegozafermin Demonstrated Robust Liver Fat Reduction With High Responder Rates ≥30% Relative Reduction in Liver Fat ≥50% Relative Reduction in Liver Fat Cohort 4 (27mg QW) 86% 71% Cohort 6 (36mg QW)
Slide 10: Pegozafermin Significantly Reduced ALT
Pegozafermin Significantly Reduced ALT With Greater Reduction Observed in Patients With Elevated Baseline ALT * * Cohort 4 and 6: Pre-planned sensitivity analysis; MMRM LS Mean at week 13; *** p<0.001 versus placebo Cohort 7: p value for change from baseline based on MMRM analysis; Data from week 20
Slide 11: Clinically Meaningful Improvements in Lipids
Pegozafermin Demonstrated Clinically Meaningful Improvements in Lipids *p<0.05 ***p<0.001 *** *** *** * p value for change from baseline based on MMRM analysis
Slide 12: Improvement on HbA1c and Adiponectin With Body Weight Reduction
Pegozafermin Demonstrated Clinically Meaningful Improvement on HbA1c and Adiponectin With Notable Body Weight Reduction (Cohort 7) p value for change from baseline based on MMRM analysis; all data are from cohort 7 Patients with baseline HbA1c ≥6.5% were on an average of 2 anti-diabetic medications
Slide 13: Pegozafermin Robustly Improved NAFLD Activity Score
Proportion of patients ≥2pt Improvement in NAS* Proportion of patients Pegozafermin Robustly Improved NAFLD Activity Score (NAS) and All Components of NAS (Cohort 7) 63% of patients had ≥2point improvement in NAS and no worsening of fibrosis* (primary endpoint) 100% of patients had improvement or no
Slide 14: Changes on Key Histological Efficacy Endpoints
Proportion of patients NASH Resolution* ≥1 Stage Improvement in Fibrosis** (95% CI: 13%-57%) (95% CI: 9%-51%) Pegozafermin Demonstrated Clinically Meaningful Changes on Key Histological Efficacy Endpoints (Cohort 7) *and no worsening of fibrosis **and no worsening of NASH *** In the post-hoc explora
Slide 15: Beneficial Effects in Subset of Patients with F4 Fibrosis
Pegozafermin Showed Beneficial Effects in Subset of Patients with F4 Stage Fibrosis *Patients assessed with F4 fibrosis by 2+ panel pathologists **N=5; one outlier with poor quality measurement was excluded. ***VCTE >20% reduction; FAST score ≤0.35. Loomba et al AASLD 2022 Fibrosis improvement ≥1 st
Slide 16: Improved Scores Across Non-Invasive Tests
Pegozafermin Substantially Improved Scores Across Non-Invasive Tests (NITs) Correlated with Advanced Fibrosis Mean Relative Change From Baseline -4.2 kPa -0.47 -0.29 -28%*** -76%*** -19%** -20%*** VCTE: Liver stiffness measure using FibroScan®; FAST score: Liver stiffness (VCTE) and steatosis (CAP)
Slide 17: Favorable Safety and Tolerability in NASH Study
No treatment-related serious adverse events; only 1 treatment-related discontinuation Pooled pegozafermin treatment related AEs observed in ≥10% of patients were: Increased appetite (13%) vs placebo (0%) Diarrhea (13%) vs placebo (11%) Nausea (12%) vs placebo (11%) Most GI AEs were mild and of short
Slide 18: Comparative Profile of FGF21 Analogs in NASH
Comparative Profile of FGF21 Analogs in NASH Note: All data regarding third-party molecules on this slide are based on third-party studies and not our own. Conclusions on this slide are not based on head-to-head results * based on range including histology assessment from 3-panel read and post-hoc e
Slide 19: Effects On Non-Invasive Markers vs Other NASH Drugs
Pegozafermin Shows Similar/Superior Effects On Non-Invasive Markers To Other NASH Drugs in Development * EFX data are reported from the 16-week phase 2a BALANCED trial Note: All data regarding third-party molecules on this slide are based on third-party studies and not our own. Conclusions on this s
Slide 20: Phase 2b (ENLIVEN) NASH Trial Design
Phase 2b (ENLIVEN) NASH Trial Design F2-F3 NASH; NAS ≥4 KEY INCLUSION CRITERIA MRI-PDFF Liver Biopsy B SCREENING RANDOMIZATION B B PLACEBO (QW or Q2W) Pegozafermin 30mg QW Pegozafermin 44mg Q2W Pegozafermin 15mg QW PLACEBO Q2W Pegozafermin 30mg QW Pegozafermin 44mg Q2W Pegozafermin 15mg QW MAIN STUD
Slide 21: Key Readthroughs to ENLIVEN Trial
Trial design helps reduce/minimize variability Large sample size provides robust powering on key dosing arms Three-panel consensus reading methodology for baseline and end of treatment biopsies to minimize reader variability Positive histology results from competitive trials de-risk ENLIVEN study Si
Slide 22: Opportunity in Severe Hypertriglyceridemia (SHTG)
Opportunity in Severe Hypertriglyceridemia (SHTG)
Slide 23: Pegozafermin Could Offer an Important New Treatment Option for SHTG
Pegozafermin Could Offer an Important New Treatment Option for SHTG Large growing patient population with significant health risks; overlap with NASH patient population Increasing TG levels increase risk of acute pancreatitis, cardiovascular disease and all-cause mortality Emerging evidence of the c
Slide 24: Phase 2 SHTG Trial Design
– Phase 2 SHTG Trial Design 8 Weeks SCREENING RANDOMIZATION SAFETY FOLLOW-UP 36mg Q2W Pegozafermin (n=16) 27mg QW Pegozafermin (n=18) 18mg QW Pegozafermin (n=17) 9mg QW Pegozafermin (n=16) PLACEBO (n=18) Safety analysis set, n=85 (patients who received at least 1 dose) Full analysis set, n=82 (patie
Slide 25: Significantly Reduces Triglycerides Across All Dose Groups
Pegozafermin Significantly Reduces Triglycerides Across All Dose Groups Primary Endpoint Median % Change in Triglycerides from Baseline at Week 8 Q2W QW p value vs placebo for change from baseline based on Wilcoxon Rank-Sum Test Full Analysis Set; * p<0.05; ** p<0.01; *** p<0.001 vs. placebo QW: Eve
Slide 26: Decrease in Triglycerides on Top of Background Therapy
Q2W QW Median % Change in Triglycerides from Baseline at Week 8 Pegozafermin Shows Significant Decrease in Triglycerides on Top of Background Therapy Not On Background Therapy On Background Therapy n=6 n=8 n=8 n=6 n=8 n=11 n=8 n=9 n=10 n=8 Background therapy defined as concomitant lipid-modifying th
Slide 27: Decrease in Triglycerides at Different Threshold Levels
Pegozafermin Shows Significant Decrease in Triglycerides at Different Threshold Levels B. TG Normalization (<150mg/dL, <200mg/dL) Analysis via unstratified Chi-square Test comparing the individual PGZ groups vs placebo. * p<0.05; ** p<0.01; *** p<0.001 vs. placebo TG Responders defined as patients w
Slide 28: Improvements in Non-HDL-C and Apo-B
Full Analysis Set; * p<0.05; ** p<0.01; *** p<0.001 vs. placebo based on MMRM analysis Pegozafermin Demonstrated Clinically Meaningful Improvements in Non-HDL-C and Apo-B – Key Marker of CV Risk Q2W QW Mean % Change from Baseline at Week 8 Non-HDL-C 218 Baseline (mg/dL): 216 203 202 215 Mean % Chang
Slide 29: Significant Reduction in Liver Fat
Mean Relative Reduction in Liver Fat vs Baseline at Week 8 Pegozafermin Demonstrated Significant Reduction in Liver Fat Liver Fat Is an Important Potentiator of CV Risk MRI Analysis Set; p value vs placebo based on ANCOVA analysis *p <0.05 vs. placebo Post-hoc analysis of patients with follow-up MRI
Slide 30: Improvement on HbA1c That May Increase With Longer Treatment
Pegozafermin Demonstrated Improvement on HbA1c that May Increase With Longer Treatment Full analysis set; MMRM analysis Absolute Change in HbA1c at Week 8 Pooled Pooled Placebo Placebo Absolute change in HbA1c in 20-week NASH study Study BIO89-100-002; Cohort 7: n=10 at PGZ 27 mg QW HbA1c: Baseline:
Slide 31: Favorable Safety/Tolerability in Phase 2 Study
Pooled pegozafermin treatment related Adverse Events (AEs) observed in ≥7.5% of patients were: Nausea (10%), diarrhea (9%) and injection site reaction (9%) vs placebo (0%) All Gastrointestinal (GI) AEs were Grade 1 or 2 No Grade 3 or higher AEs No treatment-related SAEs; 2 treatment-related disconti
Slide 32: Phase 3 Program Initiation Planned in First Half of 2023
Phase 3 Program Initiation Planned in First Half of 2023 Regulatory FDA feedback supports advancement into Phase 3 FDA feedback confirms key elements of the overall Phase 3 development program* Primary endpoint: TG reduction from baseline (anticipated to be assessed at the 26-week timepoint) Propose
Slide 33: SHTG Represents a Large Population with High Unmet Need
SHTG Represents a Large Population with High Unmet Need 900k 800k CONTROLLED POORLY MANAGED Prevalence Up to 4 million drug treated ~1.7 MILLION UN-treated ~1.1 MILLION Diagnosed ~2.8 million PEGOZAFERMIN TARGET POPULATION Co-morbidity Prevalence in SHTG population Fatty Liver Disease (NAFLD) Up to
Slide 34: Pegozafermin Delivers on Key Attributes for Successful SHTG Therapy
Pegozafermin Delivers on Key Attributes for Successful SHTG Therapy RoA: Route of Administration. Source: Physician Interviews; ClearView Analysis, 2022. Hierarchy of Attributes for SHTG Therapy Major Influence Minor Influence Modest Influence RoA/Dosing RoA and dosing were seen as the least influen
Slide 35: Pegozafermin Profile Supports Utilization Over Current SoC
For triglyceride reduction: ✔✔✔ = ≥60%, ✔✔ = 31%-59%, ✔ = ≤30% In Development Approved Pegozafermin Potential APOC3 Potential Fibrates Prescription Fish Oils Statins Pegozafermin Potential APOC3 Fibrates Vascepa Lovaza Statins Triglyceride reduction ✔✔✔ ✔✔✔ ✔✔ ✔ ✔✔ ✔✔ Liver fat reduction ✔ Worsens l
Slide 36: Significant Peak Sales Opportunity for Pegozafermin in SHTG
Poorly controlled patients demonstrate TG >500 mg/dL with Standard of Care use (i.e., OM3FAs, fibrates, statins); Source: Physician Interviews, Payer Interviews; ClearView Analysis, 2022. Significant Peak Sales Opportunity for Pegozafermin in SHTG 800k POORLY MANAGED PATIENTS 25-30% pegozafermin pre
Slide 37: Financial Position Summary
Financial Position Summary Cash, cash equivalents and short-term investments ~$191.3M pro forma1 cash as of Dec 31, 2022 and up to $100M credit facility2 1 Pro forma cash includes $25 million drawn under the K2 HealthVentures credit facility net of $20 million repaid under the SVB term loan facility
Slide 38: Corporate Highlights
Highly competitive profile with Phase 2 results demonstrating robust efficacy across multiple histological and metabolic endpoints with favorable tolerability profile Well-powered study with three-panel consensus biopsy reading method to minimize variability Nonalcoholic Steatohepatitis (NASH) – Pha
Slide 39: Appendix
Appendix
Slide 40: Experienced Management Team Positions 89bio for Success
Experienced Management Team Positions 89bio for Success Rohan Palekar CEO CEO, CCO experience Commercial, strategy, and R&D experience Hank Mansbach, MD CMO 20+ years biopharma and R&D leadership in clinical development and medical affairs Ryan Martins CFO CFO, Strategy/IR, finance, sell-side experi
Slide 41: Pegozafermin Exhibits Highly Potent FGF Receptor Agonism
Pegozafermin Exhibits Highly Potent FGF Receptor Agonism Pegozafermin has the potential to reproduce the beneficial metabolic effects of native FGF21 nd – not determined; rhFGF19 EC50 at FGFR4 = 1.7 ± 0.4 * Receptor agonism measured in L6 cells expressing β-klotho and either FGF Receptor 1c, 2c, 3c,
Slide 42: NASH Phase 1b/2a Trial Baseline Characteristics
NASH Phase 1b/2a Trial Baseline Characteristics: Consistent Across Cohorts Parameter Mean or % Cohorts 1-6 (n=81) Cohort 7 (n=20) Age (years) 51.9 58.4 Female 61.7% 75.0% Weight (kg) 93.6 104.6 BMI (kg/m2) 34.6 37.0 Type 2 Diabetes 45.7% 85.0% % F2 / % F3 N/A 35% / 65% NAS N/A 5.3 MRI-PDFF (%) 21.3
Slide 43: Baseline Characteristics – Putative NASH F4 Fibrosis Patients
Parameter Mean or % Patients with putative F4 fibrosis (n=6) Age (years) 60.9 Female 100% Weight (kg) 92.0 BMI (kg/m2) 33.9 Type 2 Diabetes (%) 83 MRI-PDFF (%) 18.25 ALT (U/L) 40.8 AST (U/L) 34.5 Fibroscan VCTE (kPa) 18.42 HbA1c (%) 6.6 Triglycerides (mg/dL) 161.1 Albumin (g/dL) 4.33 Platelets (x103
Slide 44: Baseline Characteristics (ENTRIGUE)
Baseline Characteristics (ENTRIGUE) Represents an Advanced Population at High Risk for CV Disease Parameter Mean or % Placebo (n=18) PGZ Pooled (n=67) PGZ 9mg QW (n=16) PGZ 18mg QW (n=17) PGZ 27mg QW (n=18) PGZ 36mg Q2W (n=16) Total (n=85) Age (years) 57.5 52.7 54.6 49.2 53.9 53.1 53.7 Male (%) 66.7
Slide 45: Baseline Characteristics (ENTRIGUE): Background Therapy
Baseline Characteristics (ENTRIGUE): Approximately 50% on Background Therapy Represents Real World Setting Placebo (n=18) PGZ Pooled (n=67) PGZ 9mg QW (n=16) PGZ 18mg QW (n=17) PGZ 27mg QW (n=18) PGZ 36mg Q2W (n=16) Total (n=85) Any background therapy 61% 54% 50% 53% 61% 50% 55% Statin* 50% 43% 38%
Slide 46: Decrease in Triglycerides on Top of Statins, Fish Oils and Fibrates
Pegozafermin Showed Significant Decrease in Triglycerides on Top of Statins, Prescription Fish Oils and Fibrates (ENTRIGUE) Full Analysis Set Background therapy defined as concomitant lipid-modifying therapy Median % Change in Triglycerides from Baseline at Week 8 Placebo n=9 PGZ pooled n=28 Placebo
Slide 47: Pegozafermin Significantly Reduces Apolipoprotein C3 Levels
Pegozafermin Significantly Reduces Apolipoprotein C3 Levels (ENTRIGUE) Median % Change in ApoC3 (mg/dL) from Baseline at Week 8 Q2W QW p value vs placebo for change from baseline based on Wilcoxon Rank-Sum Test Full Analysis Set; * p<0.05; ** p<0.01; *** p<0.001 vs. placebo Mean baseline ApoC3: 29.5